The rising incidence of eye infections such as fungal keratitis, is a key driver of the market. Factors such as poor hygiene practices, ocular trauma, exposure to environmental pathogens, and the spread of drug-resistant fungal strains contribute to the growing burden of eye infections globally.
As the incidence of fungal keratitis continues to rise, there is a corresponding increase in the demand for effective fungal keratitis treatment options, including antifungal medications and surgical interventions.
Additionally, the increasing prevalence of contact lens wear is a significant driver in the market, as it elevates the risk of microbial keratitis, including fungal keratitis.
The growing popularity of contact lenses for vision correction, prolonged wear, improper hygiene practices, and extended overnight use contribute to corneal susceptibility to fungal infection. This trend underscores the need for effective management strategies, thereby supporting the growth of market.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Global fungal keratitis treatment market was valued at USD 875.4 million in 2023 and is anticipated to grow at 6.1% CAGR from 2024
The geriatric segment in the fungal keratitis treatment industry is anticipated to reach USD 711.2 million by 2032, due to age-related changes in the immune system, ocular surface, and underlying medical conditions such as diabetes and immunosuppression.
North America fugal keratitis treatment market was valued at USD 353.7 million in 2023 and is anticipated to reach USD 585.6 million by 2032, owing to advanced healthcare infrastructure, high prevalence of risk factors and stringent regulatory framework.
Alvogen , Aurolab , Bausch Health Companies Inc., Eyevance Pharmaceuticals LLC , Gilead Biosciences, Inc. , Glenmark Pharmaceuticals Ltd., Leadiant Biosciences, Inc., Merck & Co. Inc., Novo Holdings A/S (Xellia Pharmaceuticals) and Pfizer Inc.